Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Gross Profit: 2018-2024

Historic Gross Profit for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to $97.0 million.

  • Akebia Therapeutics' Gross Profit rose 112.24% to $49.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.8 million, marking a year-over-year increase of 333.24%. This contributed to the annual value of $97.0 million for FY2024, which is 251.22% up from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Gross Profit is $97.0 million, which was up 251.22% from -$64.1 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Gross Profit peaked at $206.9 million during FY2022, and registered a low of -$64.1 million during FY2023.
  • For the 3-year period, Akebia Therapeutics' Gross Profit averaged around $79.9 million, with its median value being $97.0 million (2024).
  • In the last 5 years, Akebia Therapeutics' Gross Profit surged by 3,426.73% in 2021 and then plummeted by 131.00% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Gross Profit (Yearly) stood at -$1.8 million in 2020, then skyrocketed by 3,426.73% to $61.0 million in 2021, then soared by 239.32% to $206.9 million in 2022, then tumbled by 131.00% to -$64.1 million in 2023, then skyrocketed by 251.22% to $97.0 million in 2024.